BioPharma Boosted on Analyst Upgrade

The firm also raised its price target to $71 from $48

Assistant Editor
Oct 7, 2020 at 9:14 AM
facebook twitter linkedin


The shares of PTC Therapeutics Inc (NASDAQ:PTCT) are up 3.8% at $51.50 in pre-market trading, after J.P. Morgan Securities upgraded the stock to "overweight" from "neutral," with an added price-target hike to $71 from $48. The firm noted that current shares do not reflect the biopharmaceutical company's Huntington's program or acquired gene therapy, and offer an attractive long-term entry-point.

Today's pop has PTC stock looking to topple pressure at the $51 level, which has rejected the stock's rallies since its late-July dip. Year-to-date, the stock is up around 6%. 

Coming into today, analysts were already leaning bullish on PTCT, with six of the nine in coverage at a "buy" or better and the remaining three at a "hold." Meanwhile, the 12-month consensus price target of $61.18 is a 23.3% premium to last night's close. 

Lastly, though short interest has begun to fall off, down 21.2% during the last two reporting periods, the 4.96 million shares sold short still account for 7.6% of the stock's available float. In other words, it would take nearly seven days to buy back these bearish bets at PTC stock's average pace of trading. 

Celebrate 40 Years of Schaeffer's With 4 FREE Stock Picks!


 




 
Special Offers from Schaeffer's Trading Partners